{"id":2676,"date":"2026-08-24T10:00:00","date_gmt":"2026-08-24T14:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2676"},"modified":"2026-08-24T19:00:11","modified_gmt":"2026-08-24T23:00:11","slug":"precision-biosciences-doses-first-patient-in-pbgene-dmd-gene-editing-trial","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2676","title":{"rendered":"Precision BioSciences Doses First Patient in PBGENE-DMD Gene-Editing Trial"},"content":{"rendered":"

Company:<\/strong> Precision BioSciences · Asset:<\/strong> PBGENE-DMD · Platform:<\/strong> ARCUS Gene Editing · Indication:<\/strong> Duchenne Muscular Dystrophy · Date:<\/strong> August 24, 2026<\/p>\n

\"20260824_Precision_BioSciences_PBGENE_DMD_Technology_and_Modalities\"<\/p>\n

Summary<\/h4>\n

Precision BioSciences disclosed that the first participant received PBGENE-DMD in the Phase 1\/2a FUNCTION-DMD trial. The program uses two ARCUS nucleases delivered in one AAV vector to excise DMD exons 45–55 and create an endogenous, internally deleted dystrophin intended to resemble a Becker-like, near-full-length protein. This is the first human exposure milestone for the program; no safety, editing, dystrophin-expression or functional data are yet available.<\/p>\n

What Happened<\/h4>\n

The first participant was dosed earlier in August at Arkansas Children’s Hospital. FUNCTION-DMD is an open-label, single-arm study planned to enroll up to 18 ambulatory boys aged 2–7 whose mutations are amenable to exon 45–55 excision. Part 1 may enroll up to six participants for initial safety and dose confirmation, followed by an expansion of up to 12 participants. The registered intervention is a single intravenous dose with structured short-term immunomodulation; primary evaluation centers on treatment-emergent and serious adverse events, with additional assessments of dystrophin expression and functional outcomes over approximately 130 weeks. Precision expects initial safety data by year-end 2026, which is company guidance rather than a confirmed release date. PBGENE-DMD holds FDA Fast Track and Orphan Drug designations, which can facilitate development and review but do not establish efficacy, safety or approvability.<\/p>\n

Deep Analysis<\/h4>\n

The mechanistic distinction is that PBGENE-DMD edits the endogenous DMD locus rather than supplying a separate microdystrophin transgene. Removing exons 45–55 could restore the reading frame for a broad mutation hotspot, the company estimates covering up to 60% of boys with DMD, and generate a substantially larger dystrophin than AAV microdystrophin constructs. Whether this yields better sarcolemmal localization, mechanical function or durability in human muscle is unknown. Translation depends on systemic AAV delivery reaching enough skeletal and cardiac myonuclei, both nucleases cutting the intended alleles efficiently, productive joining of the two breaks, and durable protein expression without unacceptable vector- or editor-related toxicity.<\/p>\n

Large-deletion editing introduces risks beyond ordinary transgene delivery, including incomplete excision, unintended junctions, inversions, translocations, off-target cleavage and heterogeneous editing across muscles. Manufacturing must consistently package the dual-nuclease cassette within one vector and control potency, full-to-empty capsid ratio, impurities and lot comparability. Pre-existing AAV9 antibodies, immunomodulation tolerance and inability to readily redose may further constrain eligibility and rescue options. First dosing validates trial execution and product availability, not therapeutic activity or competitive displacement.<\/p>\n

Company and Product Background<\/h4>\n

Duchenne muscular dystrophy is an X-linked disorder caused by pathogenic DMD variants that disrupt dystrophin, destabilizing the muscle-cell membrane and driving progressive skeletal, respiratory and cardiac decline. Exon 45–55 is a major mutation hotspot; restoring the reading frame can produce an internally deleted dystrophin analogous to proteins observed in some milder Becker muscular dystrophy genotypes. PBGENE-DMD uses Precision’s ARCUS platform, a compact nuclease architecture derived from homing endonucleases, packaging two complementary nucleases in a single AAV intended to cut on either side of exons 45–55, with cellular repair joining the remaining ends to create an in-frame DMD transcript. Competitive alternatives include corticosteroids, exon-skipping oligonucleotides, approved or investigational microdystrophin gene transfer, other gene-editing approaches, and emerging cell or RNA strategies.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Clinical Milestone<\/td>\nFirst participant dosed in Phase 1\/2a FUNCTION-DMD<\/td>\n<\/tr>\n
Editing Design<\/td>\nTwo ARCUS nucleases in one AAV excise DMD exons 45–55<\/td>\n<\/tr>\n
Patient Reach<\/td>\nCompany estimates hotspot may cover up to 60% of boys with DMD (unconfirmed in trial)<\/td>\n<\/tr>\n
Trial Design<\/td>\nOpen-label; up to 18 ambulatory boys aged 2–7; safety-led dose confirmation and expansion<\/td>\n<\/tr>\n
Catalyst<\/td>\nInitial safety data guided for year-end 2026 (company guidance)<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A differentiated, broad-hotspot in-vivo editing design could overcome a structural limitation of microdystrophin gene transfer by producing a larger endogenous dystrophin, and the single-vector dual-nuclease design may improve coordinated cellular delivery relative to two-vector strategies.<\/p>\n

Bear case:<\/strong> The program inherits systemic AAV constraints (pre-existing antibodies, limited redosing) while adding permanent nuclease and double-strand-break risks, and no human evidence yet shows adequate editing, correct junction formation, durable protein production, or functional benefit.<\/p>\n

InSilens Take<\/h4>\n

Human dosing moves a differentiated in-vivo DMD editing design from preclinical promise to a testable clinical thesis. The important question is not whether exon 45–55 can be removed in principle, but whether systemic delivery can generate enough correctly edited, durable dystrophin across skeletal and cardiac muscle without unacceptable immune, hepatic or genomic risk. First dosing answers none of those questions yet.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> High on facts, Low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Precision BioSciences disclosed that the first participant received PBGENE-DMD in the Phase 1\/2a FUNCTION-DMD trial. The program uses two ARCUS nucleases delivered in one AAV vector to excise DMD exons 45\u201355 and create an…<\/p>\n","protected":false},"author":1,"featured_media":2681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[424,84,369,225],"class_list":["post-2676","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-arcus-nuclease","tag-duchenne-muscular-dystrophy","tag-gene-editing","tag-precision-biosciences"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2676"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2676\/revisions"}],"predecessor-version":[{"id":2686,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2676\/revisions\/2686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2681"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}